Hepatic Fibrosis clinical trials

Explore recruiting hepatic fibrosis clinical trials.

Recruiting hepatic fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatic Fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, double-blind, placebo-controlled study on the efficacy and safety of nicotinamide in patients with liver fibrosis.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 open-label positron emission tomography TRIAL to assess changes in liver uptake of [68Ga]Ga-FAPI-46 following oral administration of single doses of AZD2389 to patients with advanced liver fibrosis (PECHORA)

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/or with Mild Cirrhosis

Slovakia, Romania

Human Pharmacology (Phase I)- Other EU CTIS Study details

Preoperative Indocyanine Green administration increases intraoperative detection of Liver Tumors in Imaging-guided surgery. A phase IV clinical trial.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis

Spain, Germany, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)

Spain, Italy, Germany, Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Hepatic Fibrosis trials by city

Hepatic Fibrosis in Toronto Hepatic Fibrosis in Vancouver Hepatic Fibrosis in Montreal Hepatic Fibrosis in Calgary Hepatic Fibrosis in Edmonton Hepatic Fibrosis in Ottawa Hepatic Fibrosis in Winnipeg Hepatic Fibrosis in Quebec City Hepatic Fibrosis in Hamilton Hepatic Fibrosis in Kitchener Hepatic Fibrosis in London Hepatic Fibrosis in Halifax Hepatic Fibrosis in New York Hepatic Fibrosis in Los Angeles Hepatic Fibrosis in Chicago Hepatic Fibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease